2. Academic Validation
  3. SAR studies on a novel series of human cytomegalovirus primase inhibitors

SAR studies on a novel series of human cytomegalovirus primase inhibitors

  • Bioorg Med Chem Lett. 2007 Apr 15;17(8):2188-92. doi: 10.1016/j.bmcl.2007.01.109.
X Chen 1,  J Adrian,  T Cushing,  H Dimaio,  L Liang,  V Mayorga,  S Miao,  M G Peterson,  J P Powers,  F Spector,  C Stein,  M Wright,  D Xu,  Q Ye,  J Jaen
Affiliations

Affiliation

  • 1 Amgen Inc., 1120 Veterans Boulevard ASF2-3, South San Francisco, CA 94080, USA. xiaoqic@amgen.com
PMID: 17329103 DOI: 10.1016/j.bmcl.2007.01.109
Abstract

A novel series of imidazolylpyrimidines were found to possess inhibitory activity against the human CMV UL70 primase. Extensive SAR studies on an HTS lead led to potent, orally bioavailable compounds with anti-CMV IC(50) values of 150 nM in both viral yield and viral DNA replication assays and with a much reduced cytotoxicity compared to marketed treatments ganciclovir and cidofovir.

Figures